My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 556

    1.

    Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.

    Rothberg MB, Bellantonio S, Rose DN.

    Ann Intern Med. 2003 Sep 2;139(5 Pt 1):321-9.PMID: 12965940 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Cost-effectiveness of newer treatment strategies for influenza.

    Smith KJ, Roberts MS.

    Am J Med. 2002 Sep;113(4):300-7.PMID: 12361816 [PubMed - indexed for MEDLINE]Related articles

    3.

    Summaries for patients. Cost-effective management of flu in adults older than 65 years of age.

    [No authors listed]

    Ann Intern Med. 2003 Sep 2;139(5 Pt 1):I27. No abstract available. PMID: 12965955 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Management of influenza symptoms in healthy adults.

    Rothberg MB, He S, Rose DN.

    J Gen Intern Med. 2003 Oct;18(10):808-15.PMID: 14521643 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.

    Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED.

    Ann Intern Med. 2002 Aug 20;137(4):225-31.PMID: 12186512 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.

    Rothberg MB, Fisher D, Kelly B, Rose DN.

    Arch Pediatr Adolesc Med. 2005 Nov;159(11):1055-62.PMID: 16275797 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Antiviral drugs in influenza: an adjunct to vaccination in some situations.

    [No authors listed]

    Prescrire Int. 2006 Feb;15(81):21-30.PMID: 16548114 [PubMed - indexed for MEDLINE]Related articles

    8.

    Antiviral agents for influenza: a comparison of cost-effectiveness data.

    Lynd LD, Goeree R, O'Brien BJ.

    Pharmacoeconomics. 2005;23(11):1083-106. Review.PMID: 16277546 [PubMed - indexed for MEDLINE]Related articles

    9.

    Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

    Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

    Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170. Review.PMID: 14609480 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.

    O'Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M.

    Value Health. 2003 Mar-Apr;6(2):116-25.PMID: 12641862 [PubMed - indexed for MEDLINE]Related articles

    11.

    Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.

    Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K.

    Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246. Review.PMID: 19215705 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.

    Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R.

    Eur J Health Econ. 2005 Sep;6(3):244-52.PMID: 15875227 [PubMed - indexed for MEDLINE]Related articles

    13.

    Antiviral therapy for influenza virus infections.

    Prober CG.

    Semin Pediatr Infect Dis. 2002 Jan;13(1):31-9. Review.PMID: 12118841 [PubMed - indexed for MEDLINE]Related articles

    14.

    Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.

    Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI.

    J Am Geriatr Soc. 2005 Mar;53(3):444-51.PMID: 15743287 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.

    Vindt Holm M, Gyldmark M, Holme Hansen E.

    Pharm World Sci. 2004 Dec;26(6):339-45.PMID: 15683104 [PubMed - indexed for MEDLINE]Related articles

    16.

    Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.

    Rothberg MB, Rose DN.

    Am J Med. 2005 Jan;118(1):68-77.PMID: 15639212 [PubMed - indexed for MEDLINE]Related articles

    17.

    Summaries for patients. Influenza vaccination or antiviral treatment for healthy working adults: an economic analysis.

    [No authors listed]

    Ann Intern Med. 2002 Aug 20;137(4):I22. No abstract available. PMID: 12186536 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

    Sander B, Hayden FG, Gyldmark M, Garrison LP Jr.

    Pharmacoeconomics. 2006;24(4):373-86.PMID: 16605283 [PubMed - indexed for MEDLINE]Related articles

    19.

    Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis.

    Schwarzinger M, Housset B, Carrat F.

    Pharmacoeconomics. 2003;21(3):215-24.PMID: 12558471 [PubMed - indexed for MEDLINE]Related articles

    20.

    Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.

    Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A, Nicholson KG.

    Value Health. 2008 Mar-Apr;11(2):160-71.PMID: 18380629 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity